The Role of the Adenosinergic Pathway in Resistance to Hypomethylating Agents in Patients with High-Risk Myelodysplastic Syndromes

The authors investigated the expression of CD39, CD73 and related adenosinergic pathways and their clinical associations in T cells of higher-risk myelodysplastic syndromes patients undergoing hypomethylating agent therapy.